PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 126-150 of 369

  • CAL-130 Racemate
    Cat. No.
    A20942

    CAL-130 Racemate

    Synonyms: CAL130

    CAL-130 Racemate is the racemate of CAL-130. CAL-130 Racemate is a PI3Kδ inhibitor.

    1 mg
    $315.00
    5 mg
    $955.00
    All 6 sizes
  • SAR405
    Cat. No.
    A21345

    SAR405

    SAR405 is a first-in-class, selective, and ATP-competitive PI3K class III (PI3KC3) isoform Vps34 inhibitor (IC50=1.2 nM; Kd=1.5 nM).

    1 mg
    $40.00
    2 mg
    $75.00
    All 7 sizes
  • Alpelisib hydrochloride
    Cat. No.
    A21794

    Alpelisib hydrochloride

    Synonyms: BYL-719 hydrochloride; BYL 719

    Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent, orally active, and selective PI3Kα inhibitor with IC50s of 5 nM, 250 nM, 290 nM and 1200 nM for p110α, p110γ, p110δ, and p110β, respectively.

    1 mg
    $315.00
    5 mg
    $955.00
    All 6 sizes
  • Rigosertib sodium
    Cat. No.
    A21824

    Rigosertib sodium

    Synonyms: ON-01910 sodium; ON01910

    Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle.

    5 mg
    $25.00
    10 mg
    $45.00
    All 7 sizes
  • Rigosertib
    Cat. No.
    A21868

    Rigosertib

    Synonyms: ON-01910

    Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle.

    2 mg
    $25.00
    5 mg
    $50.00
    All 5 sizes
  • Umbralisib R-enantiomer
    Cat. No.
    A21993

    Umbralisib R-enantiomer

    Synonyms: TGR-1202 R-enantiomer; TGR1202; RP5264 R-enantiomer; RP 5264

    Umbralisib R-enantiomer (TGR-1202 R-enantiomer) is a PI3Kδ inhibitor, which is the less active enantiomer of TGR-1202.

    1 mg
    $190.00
    2 mg
    $370.00
    All 8 sizes
  • GNE-490
    Cat. No.
    A22231

    GNE-490

    GNE-490 is a highly selective pan-PI3K inhibitor that demonstrates selectivity over mTOR.

    1 mg
    $70.00
    2 mg
    $110.00
    All 9 sizes
  • Gallein
    Cat. No.
    A22304

    Gallein

    Synonyms: Pyrogallol phthalein

    Gallein is a G protein βγ (Gβγ) subunit signalling inhibitor. Gallein disrupts the interaction of Gβγ subunits with the PI3Kγ. Anticancer agent.

    5 mg
    $25.00
    10 mg
    $35.00
    All 6 sizes
  • SRX3207
    Cat. No.
    A22305

    SRX3207

    SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.

    1 mg
    $45.00
    5 mg
    $125.00
    All 7 sizes
  • Nemiralisib
    Cat. No.
    A22373

    Nemiralisib

    Synonyms: GSK2269557 (free base)

    Nemiralisib (GSK2269557 free base) is a potent and highly selective PI3Kδ inhibitor with a pKi of 9.9.

    1 mg
    $35.00
    2 mg
    $50.00
    All 8 sizes
  • PI3Kδ-IN-5
    Cat. No.
    A22381

    PI3Kδ-IN-5 (Compound 7n)

    Synonyms: Compound 7n

    Selective PI3Kδ Inhibitor 1 (compound 7n) is an inhibitor of PI3Kδ with an IC50 of 0.9 nM and >1000-fold selectivity against other class I PI3K isoforms [PI3K α/γ/β=3670/1460/21300 nM].

    1 mg
    $45.00
    2 mg
    $85.00
    All 8 sizes
  • AZD6482 (S-isomer)
    Cat. No.
    A22606

    AZD6482 (S-isomer)

    AZD6482 (S-isomer), CAS#1173900-37-2, is an isomer of AZD6482 (MedKoo Cat#406268) with S-configuration. AZD6482 is a potent, selective and ATP competitive PI3Kβ inhibitor (IC(50) 0.01 μm).

    25 mg
    $1,665.00
    50 mg
    $2,175.00
    All 3 sizes
  • MDK34597
    Cat. No.
    A22652

    MDK34597

    MDK34597 is a PI3K inhibitor. MDK34597 has CAS#371934-59-7, the last 5 digits of which were used for its name. MDK34597 is an analog of PI-103 and acts as a dual PI3K/mTOR Inhibitor.

    1 mg
    $50.00
    5 mg
    $130.00
    All 6 sizes
  • MTX-531
    Cat. No.
    A24175

    MTX-531

    MTX-531 is an orally active small molecule that inhibits EGFR (IC50 = 14.7 nM) and multiple PI3K isoforms, with IC50 values of 6.4 nM (PI3Kα), 233 nM (PI3Kβ), 8.3 nM (PI3Kγ), and 1.1 nM (PI3Kδ), demonstrating potent antitumor activity. Additionally, MTX-531 functions as a weak PPARγ agonist (IC50 = 2.5 µM), which may mitigate PI3K inhibitor-induced hyperglycemia.

    5 mg
    $144.00
    10 mg
    $248.00
    All 4 sizes
  • PI3K/Akt/mTOR-IN-2
    Cat. No.
    A24214

    PI3K/Akt/mTOR-IN-2

    PI3K/Akt/mTOR-IN-2 is an inhibitor of the PI3K/AKT/mTOR signaling pathway with demonstrated anticancer activity. It selectively inhibits the proliferation of MDA-MB-231 cells with an IC50 of 2.29 μM and induces cell cycle arrest and apoptosis, making it a promising candidate for cancer research.

    5 mg
    $72.00
    10 mg
    $124.00
    All 4 sizes
  • SRX3177
    Cat. No.
    A24272

    SRX3177

    SRX3177 is a potent triple inhibitor targeting CDK4/6, PI3K, and BRD4, with IC50 values of

    5 mg
    $162.00
    10 mg
    $279.00
    All 4 sizes
  • SQLE-IN-1
    Cat. No.
    A24611

    SQLE-IN-1

    SQLE-IN-1 is a potent inhibitor of squalene epoxidase (SQLE). This compound effectively suppresses the proliferation and migration of Huh7 hepatocellular carcinoma cells, while also reducing cellular cholesterol synthesis. Additionally, SQLE-IN-1 promotes the upregulation of PTEN and concurrently inhibits the PI3K/AKT signaling pathway, underscoring its potential in cancer research and therapeutic applications.

    1 mg
    $75.00
    5 mg
    $185.00
    All 6 sizes
  • Tersolisib
    Cat. No.
    A24629

    Tersolisib

    Synonyms: STX-478; STX-478-101; LY4064809

    Tersolisib is a selective allosteric inhibitor of PI3Kα, specifically designed to target mutant forms of the enzyme. This compound exhibits significant anti-tumor activity, demonstrating robust and durable regression in various cancer models. Tersolisib is valuable in cancer research, particularly for studies focusing on PI3K pathway alterations and their therapeutic implications.

    1 mg
    $65.00
    5 mg
    $160.00
    All 6 sizes
  • Veratramine
    Cat. No.
    A24634

    Veratramine

    Synonyms: NSC17821; NSC23880

    Veratramine is a selective inhibitor of the PI3K/Akt/mTOR signaling pathway and serves as a modulator of SIGMAR1. This compound facilitates autophagic apoptosis in tumor cells, effectively induces G0/G1 cell cycle arrest, and diminishes epithelial-mesenchymal transition (EMT) markers, thereby reducing tumor migration. Additionally, Veratramine exhibits neuroprotective effects by inhibiting SIGMAR1 interactions with NMDAR and the phosphorylation of NMDAR Ser896, resulting in reduced neurological damage in neuropathy models. Its diverse biological activities make it suitable for research on liver cancer, osteosarcoma, and diabetic peripheral neuropathy.

    5 mg
    $25.00
    10 mg
    $35.00
    All 7 sizes
  • BBO-10203
    Cat. No.
    A24637

    BBO-10203

    BBO-10203 is a potent PI3Kα inhibitor that selectively and covalently binds to Cys242 in the RAS-Binding Domain. It inhibits both the GTP-bound and GDP-bound states of KRASG12C with an IC50 of 0.031 nM and an EC50 of 0.02 nM. By disrupting the interaction between RAS isoforms and PI3Kα, BBO-10203 effectively reduces pERK expression, suppresses cell growth, and induces G1 arrest and apoptosis. This compound is valuable for research into breast cancer, colorectal cancer, and non-small cell lung cancer.

    1 mg
    $1,585.00
    5 mg
    $3,380.00
    All 5 sizes
  • PI3K/AKT-IN-1
    Cat. No.
    A24642

    PI3K/AKT-IN-1

    PI3K/AKT-IN-1 is a potent dual inhibitor of the PI3K/AKT signaling pathway, exhibiting IC50 values of 6.99 μM for PI3Kγ, 4.01 μM for PI3Kδ, and 3.36 μM for AKT. This compound demonstrates significant anticancer activity by disrupting the PI3K/AKT axis, leading to the induction of caspase-3 dependent apoptosis. It serves as a valuable tool for research in cancer biology and therapeutic development targeting the PI3K/AKT pathway.

    1 mg
    $55.00
    5 mg
    $135.00
    All 8 sizes
  • iMDK
    Cat. No.
    A24643

    iMDK

    iMDK is a potent inhibitor of phosphoinositide 3-kinase (PI3K) and midkine (MDK), a growth factor associated with tumorigenesis. This compound has demonstrated the ability to effectively suppress non-small cell lung cancer (NSCLC) growth, particularly in combination with MEK inhibitors, while exhibiting minimal toxicity to normal cells and healthy mouse models. iMDK is a valuable tool for researchers studying cancer biology and potential therapeutic strategies targeting the PI3K/MDK signaling pathway.

    1 mg
    $45.00
    5 mg
    $105.00
    All 6 sizes
  • Zovegalisib
    Cat. No.
    A24644

    Zovegalisib

    Synonyms: RLY-2608

    Zovegalisib is an orally active allosteric inhibitor that selectively targets mutant forms of PI3Kα, exhibiting significant anti-tumor activity. This compound has demonstrated efficacy in inhibiting tumor growth in PIK3CA-mutant xenograft mouse models while exhibiting minimal effects on insulin levels. It is valuable for research into targeted cancer therapies and the exploration of PI3K signaling pathways.

    1 mg
    $65.00
    5 mg
    $330.00
    All 6 sizes

Items 126-150 of 369

Added to your cart

View Cart Checkout

    Loading...